

ClinicalTrials.gov Search Results 07/04/2022

	Title	Status	Study Results	Conditions	Interventions	Locations
1	Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences	Completed	No Results Available	•Neuroendocrine Tumors	•Other: magnetic resonance imaging	•Damien JOLLY, Reims, France
2	Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: AlphaMedix	•Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
3	Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: 177Lu-DOTATATE 25.9 GBq activity •Drug: 177Lu-DOTATATE 18.5 GBq activity	•Irst Irccs, Meldola, FC, Italy
4	Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT •Drug: CAPTEM (Capecitabine and Temozolomide) •Other: Amino-Acid Solution •Drug: Everolimus •Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)	•Washington University Alvin J. Siteman Cancer Center, Saint Louis, Missouri, United States •Memorial Sloan-Kettering Cancer Center, New York, New York, United States •University of Texas MD Anderson Cancer Center, Houston, Texas, United States •Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia •Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology, Pessac, Bordeaux, France •Nantes University Hospital Center - Hotel Dieu Hospital, Nantes, Cedex, France •Edouard Herriot Hospital, Medical Oncology Unit, Lyon, France •IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Toulouse, France •All India Institute Of Medical Sciences, Nuclear Medicine, New Delhi, Delhi, India •HCG Cancer Centre, Medical Oncology, Bangalore, Karnataka, India •and 8 more
5	Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: Lutetium-177 Octreotate	•Juravinski Cancer Centre, Hamilton, Ontario, Canada •London Health Sciences Centre, London, Ontario, Canada •Princess Margaret Cancer Centre, Toronto, Ontario, Canada •Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
6	DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor	Completed	No Results Available	•Neuroendocrine Tumor	•Dietary Supplement: Vitamin supplement; •Other: Diet advice	•University Medical Center Groningen, Groningen, Netherlands
7	PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2 •Device: PET/CT	•Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
8	Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor	Completed	No Results Available	•Neuroendocrine Tumor	•Drug: 90Y-DOTA-TOC •Drug: 68Ga-DOTA-TOC	•University of California, San Francisco, San Francisco, California, United States
9	Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor	Completed	No Results Available	•Neuroendocrine Tumor	•Drug: Pazopanib	•Samsung Cancer Center, Seoul, Korea, Republic of
10	Combination Targeted Radiotherapy in Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Other: 131-I MIBG and 111-In pentetretotide •Other: 131-I MIBG and In-111 DOTATATE	•University of Iowa, Iowa City, Iowa, United States •Department of Veteran Affairs Medical Center, Iowa City, Iowa, United States
11	The Indol Profile: Exploring the Metabolic Profile of Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Other: vena punctum	•University Medical Center Groningen, Groningen, Netherlands

	Title	Status	Study Results	Conditions	Interventions	Locations
12	PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: One injection of 68Ga-NOTA-AE105 •Device: PET/CT	•Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
13	Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.	Not yet recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: 177Lu-DOTATOC •Drug: Capecitabine	•Sahlgrenska University Hospital, Dept. of Oncology, Göteborg, Sweden •Skåne University Hospital, Dept. of Oncology, Lund, Sweden •Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden •Accademical Hospital, Uppsala, Dept. of Oncology, Uppsala, Sweden
14	Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study	Completed	No Results Available	•Neuroendocrine Tumor	•Other: Videoconsultation	•University Medical Center Groningen, Groningen, Netherlands
15	Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region	Unknown status	No Results Available	•Pancreatic Neuroendocrine Tumor		•Service D'Hematologie Et D'Oncologie, Strasbourg, France
16	Lutathera and ASTX727 in Neuroendocrine Tumours	Not yet recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: ASTX727	
17	5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'	Completed	No Results Available	•Neuroendocrine Tumors		•University Medical Center Groningen, Groningen, Netherlands
18	Telotristat With Lutathera in Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: Telotristat (Low-Dose) •Drug: Telotristat (High-Dose)	•Markey Cancer Center, Lexington, Kentucky, United States
19	Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors	Unknown status	No Results Available	•Neuroendocrine Tumors	•Drug: Recombinant anti-tumor and anti-virus protein for injection (Novaferon)	•307 Hospital of PLA, Beijing, Beijing, China
20	Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: Al18F-NOTA-octreotide •Device: PET/CT •Device: PET/MR	•Universitaire Ziekenhuizen Leuven, Leuven, Belgium
21	Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: Gallium-68 NODAGA-JR11	•Peking Union Medical College Hospital, Beijing, Beijing, China •The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
22	Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors	Not yet recruiting	No Results Available	•Neuroendocrine Tumors	•Diagnostic Test: 18F-DOPA with furosemide	•University of Alberta Hospital, Edmonton, Alberta, Canada
23	PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: Talazoparib	•Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
24	Psychosocial Screening for Neuroendocrine Tumor Patients	Unknown status	No Results Available	•Neuroendocrine Tumors		•Beijing Cancer Hospital, Beijing, Beijing, China
25	A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: Pelcitoclax	•The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China •Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China •Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
26	Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors	Withdrawn	No Results Available	•Neuroendocrine Tumors	•Radiation: MIBG-I131	•AC Camargo Cancer Center, São Paulo, SP, Brazil
27	68Ga-DOTATATE PET/CT in Neuroendocrine Tumor	Unknown status	No Results Available	•Neuroendocrine Tumors	•Drug: 68Ga-DOTATATE	•Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China
28	Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors	Not yet recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: Cabozantinib •Drug: Lu-177	•Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
29	Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: 3-[18F]Fluoro-para-hydroxyphenethylguanidine •Drug: [123I] metaiodobenzylguanidine •Diagnostic Test: Positron emission tomography/computed tomography scan •Diagnostic Test: Planar scintigraphy scan •Diagnostic Test: Single photon emission computed tomography/computed tomography scan 	•University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
30	Lithium for Low-Grade Neuroendocrine Tumors	Completed	Has Results	•Neuroendocrine Tumors	•Drug: Lithium Carbonate	•University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
31	Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities	Unknown status	No Results Available	•Neuroendocrine Tumors	•Diagnostic Test: PET/MR scan	
32	Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: F18-FDG	•Princess Margaret Cancer Centre, Toronto, Ontario, Canada
33	Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor	Unknown status	No Results Available	•Neuroendocrine Tumors	•Diagnostic Test: PET/MR scan	
34	A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +/- SSA Treatment	Recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Other: Liquid biopsies •Other: Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT) 	<ul style="list-style-type: none"> •AZ Rivierenland, Bornem, Antwerp, Belgium •AZ Klina, Brasschaat, Antwerp, Belgium •AZ Monica, Deurne, Antwerp, Belgium •Antwerp University Hospital, Edegem, Antwerp, Belgium •AZ Voorkepen, Malle, Antwerp, Belgium •ZNA, Merksem, Antwerp, Belgium •AZ Nikolaas, Sint-Niklaas, East-Flanders, Belgium •GZA, Antwerp, Belgium
35	68Ga-DOTATATE PET for Management of Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Diagnostic Test: 68Ga -DOTATATE PET scans	•Princess Margaret Cancer Centre, Toronto, Ontario, Canada
36	MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Oxaliplatin-based chemotherapy •Drug: Alkylating-based chemotherapy 	<ul style="list-style-type: none"> •Hôpital Sud - CHU Amiens, Amiens, France •CHU d'Angers, Angers, France •Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France •Hôpital Beaujon - APHP, Clichy, France •Hôpital François Mitterrand - CHU Dijon Bourgogne, Dijon, France •Centre Oscar Lambret, Lille, France •Hôpital Claude Hurriet - CHRU Lille, Lille, France •Hôpital Edouard Herriot - Hospices Civils de Lyon, Lyon, France •Hôpital Privé Jean Mermoz, Lyon, France •Institut Paoli Calmettes, Marseille, France •and 9 more
37	A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +/- SSA Treatment (Liquid-NET 2.0)	Recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Other: Liquid biopsies •Other: Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT) 	<ul style="list-style-type: none"> •Antwerp University Hospital, Edegem, Antwerp, Belgium •VITAZ, Sint-Niklaas, East-Flanders, Belgium •Bank of Cyprus Oncology Center, Nicosia, Cyprus

	Title	Status	Study Results	Conditions	Interventions	Locations
38	Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Diagnostic Test: Gallium-68 NODAGA-LM3 PET/CT •Diagnostic Test: Gallium-68 DOTA-LM3 PET/CT •Diagnostic Test: Gallium-68 DOTATATE PET/CT 	•Peking Union Medical College Hospital, Beijing, Beijing, China
39	Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue	Unknown status	No Results Available	•Neuroendocrine Tumors	•Drug: Everolimus	•Oncology Centre, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
40	Pemetrexed in Patients With Advanced Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: Pemetrexed	•Dana-Farber Cancer Center, Boston, Massachusetts, United States
41	An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: 64Cu-SARTATE	
42	Biomarker Study in Pancreatic Neuroendocrine Tumours	Unknown status	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Procedure: Core Needle Biopsy •Radiation: Computed Tomography •Radiation: 18F-FDG-PET •Procedure: Phlebotomy •Genetic: Molecular genetic analysis 	•Akademiska Sjukhuset, Uppsala, Sweden
43	A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: 64Cu-SARTATE	<ul style="list-style-type: none"> •Nepean Hospital, Kingswood, New South Wales, Australia •Royal North Shore Hospital, Sydney, New South Wales, Australia •Royal Adelaide Hospital, Adelaide, South Australia, Australia •Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
44	AI18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: AI18F-NOTA-octreotide •Device: PET/CT •Other: Venous blood samples 	•Universitaire Ziekenhuizen Leuven, Leuven, Belgium
45	Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors	Withdrawn	No Results Available	•Neuroendocrine Tumors	•Drug: Telotristat Ethyl Oral Tablet	
46	Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: [68Ga]Pentixafor	•Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
47	Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors	Recruiting	No Results Available	•Neuroendocrine Tumors	•Device: Whole Body Dynamic 68Ga-DOTATOC PET/CT	•CHRU de Brest, Brest, France
48	Endoscopic Resection for Small Rectal Neuroendocrine Tumors	Not yet recruiting	No Results Available	•Rectal Neuroendocrine Tumor	<ul style="list-style-type: none"> •Procedure: mEMR-C procedure •Procedure: ESD procedure 	
49	Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases	Suspended	No Results Available	•Neuroendocrine Tumors	•Drug: [90]Y-DOTATOC	•The Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
50	89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: 89Zr-bevacizumab •Drug: Everolimus 	•University Medical Center Groningen, Groningen, Netherlands
51	Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel	Completed	No Results Available	•Neuroendocrine Tumors	•Other: Data collection	•Ipsen Central Contact, Paris, France
52	Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan	Completed	Has Results	•Neuroendocrine Tumors	•Drug: 68Ga-DOTATOC	

	Title	Status	Study Results	Conditions	Interventions	Locations
53	Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors	Unknown status	No Results Available	•Neuroendocrine Tumors	•Drug: 177Lu-DOTA-EB-TATE 1 •Drug: 177Lu-DOTA-TATE •Drug: 177Lu-DOTA-EB-TATE 2 •Drug: 177Lu-DOTA-EB-TATE 3	•Peking Union Medical College Hospital, Beijing, China
54	Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)	Completed	No Results Available	•Neuroendocrine Tumors	•Procedure: F-18-F-DOPA	•North Shore University Hospital, Manhasset, New York, United States
55	177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors	Unknown status	No Results Available	•Neuroendocrine Tumors	•Drug: 177Lu-DOTA-EB-TATE	•Peking Union Medical College Hospital, Beijing, Beijing, China
56	A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extraprostatic Neuroendocrine Tumor	Unknown status	No Results Available	•Extraprostatic Neuroendocrine Tumor	•Drug: Tegafur •Drug: Temozolomide •Drug: Thalidomide	•Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
57	Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: 64Cu-DOTATATE	•Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
58	Study of JS001 in Patients With Advanced Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Biological: humanized anti-PD-1 monoclonal antibody	•Beijing Cancer Hospital, Beijing, Beijing, China
59	A Study of Pembrolizumab in Patients With Neuroendocrine Tumors	Completed	Has Results	•Neuroendocrine Tumors	•Drug: Pembrolizumab	•Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States •MD Anderson Cancer Center, Houston, Texas, United States
60	Treatment With SU11248 in Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: Sunitinib	•Pfizer Investigational Site, Birmingham, Alabama, United States •Pfizer Investigational Site, Birmingham, Alabama, United States •Pfizer Investigational Site, Los Angeles, California, United States •Pfizer Investigational Site, Los Angeles, California, United States •Pfizer Investigational Site, San Francisco, California, United States •Pfizer Investigational Site, Pinckneyville, Illinois, United States •Pfizer Investigational Site, Boston, Massachusetts, United States •Pfizer Investigational Site, Boston, Massachusetts, United States •Pfizer Investigational Site, Boston, Massachusetts, United States •Pfizer Investigational Site, Boston, Massachusetts, United States •Pfizer Investigational Site, St Louis, Missouri, United States •Pfizer Investigational Site, St. Louis, Missouri, United States •Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
61	A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors	Unknown status	No Results Available	•Well-differentiated Neuroendocrine Tumors	•Drug: Metformin	•Instituto do Cancer do Estado de São Paulo, Sao Paulo, SP, Brazil

	Title	Status	Study Results	Conditions	Interventions	Locations
62	A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: LEE011 •Drug: everolimus	<ul style="list-style-type: none"> •Massachusetts General Hospital, Boston, Massachusetts, United States •Dana Farber Cancer Institute, Boston, Massachusetts, United States •Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States •Memorial Sloan Kettering Cancer Center, New York, New York, United States •Md Anderson Cancer Center, Houston, Texas, United States
63	Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Other: Data collection	<ul style="list-style-type: none"> •Moffitt Cancer Center, Tampa, Florida, United States •Cancer Center of Kansas, Wichita, Kansas, United States •Ochsner Clinic Foundation, New Orleans, Louisiana, United States •Mercy Medical Center, Baltimore, Maryland, United States •Tufts Medical Center, Boston, Massachusetts, United States •Mayo Clinic, Rochester, Minnesota, United States •National Transitional Research, East Setauket, New York, United States •Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States
64	Gastrointestinal Motility in Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumor	•Device: Magnetic Tracking System (MTS) and radio-opaque markers	•Analfysiologisk afsnit, Aarhus University Hospital, Tage Hansensgade, entrance 11A, Aarhus, Denmark
65	Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Other: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide	•Instituto do Cérebro do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil
66	Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: Lenvatinib	<ul style="list-style-type: none"> •Universitätsklinik für Innere Medizin, Graz, Austria •Medizinische Universität Wien, Wien, Austria •Spedali Civili di Brescia, Brescia, Italy •Istituto Oncologico Mediterraneo, Catania, Italy •Azienda Ospedaliero Universitaria Careggi - SC di Oncologia, Firenze, Italy •IRST of Meldola, Meldola, Italy •Istituto Europeo di Oncologia - Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini, Milano, Italy •AOU Policlinico di Modena - DH Oncologico, Modena, Italy •IRCCS Napoli, Napoli, Italy •Hospital Universatorio de Verona, Verona, Italy •and 12 more
67	Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors	Unknown status	No Results Available	•Neuroendocrine Tumor	•Procedure: PET scan with Ga68-DOTANOC	•Department of Nuclear Medicine, Hadassah Medical Center, Jerusalem, Israel
68	Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy	Recruiting	No Results Available	•Neuroendocrine Tumors	•Drug: AdVince	•Endocrine Oncology Clinic, Uppsala University Hospital, Uppsala, Sweden

	Title	Status	Study Results	Conditions	Interventions	Locations
69	A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Octreotide •Drug: LAR Lanreotide •Behavioral: Questionnaires 	<ul style="list-style-type: none"> •Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States •Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States •Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States •Memorial Sloan Kettering Commack, Commack, New York, United States •Memorial Sloan Kettering West Harrison, Harrison, New York, United States •Memorial Sloan Kettering Cancer Center, New York, New York, United States •Memorial Sloan Kettering Nassau, Uniondale, New York, United States
70	Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Metronomic cyclophosphamide •Drug: Interferon-alpha 	<ul style="list-style-type: none"> •Centre Hospitalier Universitaire de Besançon, Besancon, France •Hôpital Nord Franche-Comté, Montbéliard, France
71	Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis	Completed	No Results Available	•Neuroendocrine Tumors	•Other: Metastasized intestinal NET	•University Medical Center Groningen, Groningen, Netherlands
72	Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor	Completed	No Results Available	•Neuroendocrine Tumor	<ul style="list-style-type: none"> •Other: Web-based tailored information and support system •Other: Standard care 	•University Medical Center Groningen, Groningen, Netherlands
73	Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors	Completed	Has Results	•Pancreatic Neuroendocrine Tumors	•Drug: Sunitinib	<ul style="list-style-type: none"> •Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan •National Cancer Center Hospital, Chuo-ku, Tokyo, Japan •Kyushu University Hospital, Fukuoka, Japan •Osaka Police Hospital, Osaka, Japan
74	Endoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mm	Unknown status	No Results Available	•Rectal Neuroendocrine Tumor	<ul style="list-style-type: none"> •Procedure: ESD procedure •Procedure: EMR-C procedure 	
75	68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours	Completed	No Results Available	•Neuroendocrine Tumours	•Drug: Diagnostic work up	<ul style="list-style-type: none"> •Irene Virgolini, Innsbruck, Austria •Laura Scaltriti, Guastalla, Reggio Emilia, Italy •ASMN IRCCS Reggio Emilia, Reggio Emilia, RE, Italy •Enrico Papini, Albano Laziale, Roma, Italy •Nadia Cremonini, Bologna, Italy •Fernando Cirillo, Cremona, Italy •Diego Ferone, Genova, Italy •Giovanna Pepe, Milano, Italy •Rita Conigliaro, Modena, Italy •Luppi Gabriele, Modena, Italy •and 11 more

	Title	Status	Study Results	Conditions	Interventions	Locations
76	Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: Pasireotide LAR	<ul style="list-style-type: none"> •Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States •H. Lee Moffitt Cancer Center & Research Institute SC-1, Tampa, Florida, United States •Dana Farber Cancer Institute SC-6, Boston, Massachusetts, United States •University of Texas/MD Anderson Cancer Center UT MD Anderson Cancer Ctr, Houston, Texas, United States
77	Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor	Unknown status	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Capecitabine, Dacarbazine •Drug: Capecitabine, Temozolomide 	<ul style="list-style-type: none"> •Beijing Cancer Hospital, Beijing, Beijing, China
78	A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours	Terminated	No Results Available	•Neuroendocrine Tumours		<ul style="list-style-type: none"> •Peter MacCallum Cancer Centre, East Melbourne, Australia •IUCT Oncopole, Toulouse, France •Institut Gustave Roussy, Villejuif, France •Zentralklinil Bad Berka, Bad Berka, Germany •Charité, Berlin, Germany •Klinikum rechts der Usar, München, Germany •Università degli Studi di Messina, Messina, Italy •IEO Institutio Europeo di Oncologia, Milano, Italy •Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom •Kings College Hospital, London, United Kingdom •Royal Free Hospital London, London, United Kingdom •The Christie NHS Foundation Trust, Manchester, United Kingdom
79	Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Surufatinib •Other: Placebo 	<ul style="list-style-type: none"> •Peking Union Medical College Hospital, Beijing, Beijing, China •the 307 Hospital of People's Liberation Army, Beijing, Beijing, China •Beijing Cancer Hospital, Beijing, Beijing, China •Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China •West China Hospital, Sichuan University, Chengdu, Sichuan, China
80	Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors	Completed	Has Results	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Device: PET/CT Imaging •Radiation: 68Ga-DOTA-JR11 •Radiation: 177Lu-DOTA-JR11 	<ul style="list-style-type: none"> •Memorial Sloan Kettering Cancer Center, New York, New York, United States
81	Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors	Active, not recruiting	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Surufatinib •Other: Placebo 	<ul style="list-style-type: none"> •Peking Union Medical College Hospital, Beijing, Beijing, China •the 307 Hospital of People's Liberation Army, Beijing, Beijing, China •Beijing Cancer Hospital, Beijing, Beijing, China •Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China •West China Hospital, Sichuan University, Chengdu, Sichuan, China
82	Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia	Completed	No Results Available	•Neuroendocrine Tumors		

	Title	Status	Study Results	Conditions	Interventions	Locations
83	Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	•Drug: Sulfatinib	<ul style="list-style-type: none"> •Peking Union Medical College Hospital, Beijing, Beijing, China •the 307 Hospital of People's Liberation Army, Beijing, Beijing, China •Beijing Cancer Hospital, Beijing, Beijing, China •Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China •Shanghai Pulmonary Hospital, Shanghai, Shanghai, China •West China Hospital, Sichuan University, Chengdu, Sichuan, China •The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
84	Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors	Not yet recruiting	No Results Available	•Neuroendocrine Tumors,Gastroenteropancreatic	<ul style="list-style-type: none"> •Drug: Cabozantinib •Drug: Lanreotide 	<ul style="list-style-type: none"> •National Taiwan University Hospital, Taipei, Taiwan
85	Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumor	<ul style="list-style-type: none"> •Drug: Thalidomide •Drug: Temodar 	<ul style="list-style-type: none"> •Massachusetts General Hospital, Boston, Massachusetts, United States •Dana-Farber Cancer Institute, Boston, Massachusetts, United States •Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
86	ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	Unknown status	No Results Available	•Neuroendocrine Tumors		<ul style="list-style-type: none"> •Hadassah Medical Organization, Jerusalem, Israel
87	Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors	<ul style="list-style-type: none"> •Drug: Bevacizumab •Drug: Temozolomide 	<ul style="list-style-type: none"> •Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States •Dana-Farber Cancer Insitute, Boston, Massachusetts, United States •Massachusetts General Hospital, Boston, Massachusetts, United States
88	Best Therapy for Patients With Neuroendocrine Tumors	Completed	No Results Available	•Neuroendocrine Tumors		<ul style="list-style-type: none"> •Zentralklinik Bad Berka, Bad Berka, Germany
89	Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	Unknown status	No Results Available	•Neuroendocrine Tumor	•Other: laboratory biomarker analysis	<ul style="list-style-type: none"> •Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
90	Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.	Completed	Has Results	•Neuroendocrine Tumours	•Drug: Lanreotide (Autogel formulation) and Temozolomide	<ul style="list-style-type: none"> •Oncologia Medica - Istituto Oncologico del Mediterraneo - IOM, Viagrande, Catania, Italy •Unità Operativa di Oncologia Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy •Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l., IRCCS, Meldola, Italy •Unità Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Istituto Europeo di Oncologia, IEO, Milan, Italy •Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica , Università degli Studi, Napoli, Italy •Dipartimento di Oncologia Università di Torino Ospedale San Luigi Gonzaga, Orbassano, Italy •S.C di Oncologia Medica, Azienda Ospedaliera Universitaria di Perugia, Perugia, Italy •U.O. Oncologia - Azienda Ospedaliero-Universitaria Pisana Ospedale S. Chiara, Pisa, Italy •Oncologia Medica - Istituto Tumori Regina Elena San Gallicano, Roma, Italy •OUC di Oncologia- Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Verona, Italy
91	A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers	Completed	Has Results	•Neuroendocrine Tumors	•Drug: fosbretabulin tromethamine	<ul style="list-style-type: none"> •Stanford University School of Medicine, Stanford, California, United States •Markey Cancer Center, Clinical Research Office, Lexington, Kentucky, United States •Montefiore, Bronx, New York, United States •Duke University Medical Center, Durham, North Carolina, United States •Froedtert Hospital, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
92	Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients	Completed	Has Results	•NeuroEndocrine Tumours	•Drug: lanreotide acetate	<ul style="list-style-type: none"> •Basingstoke & North Hampshire Hospital, Basingstoke, United Kingdom •Queen Elizabeth Hospital, Birmingham, United Kingdom •University Hospital Wales, Cardiff, United Kingdom •Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom •St James's University Hospital, Leeds, United Kingdom •University Hospital Aintree, Liverpool, United Kingdom •Hammersmith Hospital, London, United Kingdom •King's College Hospital, London, United Kingdom •Royal Free Hospital, London, United Kingdom •Maidstone Hospital, Maidstone, United Kingdom •and 4 more
93	A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor	Unknown status	No Results Available	•Pancreatic Neuroendocrine Tumor	<ul style="list-style-type: none"> •Drug: Tegafur and Temozolomide •Drug: Tegafur and Temozolomide combined with Thalidomide 	•Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
94	Pasireotide Treatment for Neuroendocrine Tumor	Withdrawn	No Results Available	•Gastro-enteropancreatic Neuroendocrine Tumor	<ul style="list-style-type: none"> •Drug: Pasireotide •Drug: Diazoxide 	

	Title	Status	Study Results	Conditions	Interventions	Locations
95	Study of Panobinostat in Patients With Neuroendocrine Tumors	Terminated	Has Results	•Neuroendocrine Tumors	•Drug: panobinostat (LBH589)	•University of Wisconsin, Madison, Madison, Wisconsin, United States
96	SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors	Enrolling by invitation	No Results Available	•Neuroendocrine Tumors	•Drug: 68Ga-DOTATATE PET/CT	•Jewish General Hospital, Montréal, Quebec, Canada
97	Nutrition in Gastroenteropancreatic Neuroendocrine Tumor	Active, not recruiting	No Results Available	•Gastroenteropancreatic Neuroendocrine Tumor		<ul style="list-style-type: none"> •Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain •Hospital Universitario Vall d'Hebron, Barcelona, Spain •Hospital Universitario Reina Sofia, Córdoba, Spain •Hospital Universitario Dr. Josep Trueta, Gerona, Spain •Hospital Universitario de Cabueñes, Gijón, Spain •Hospital Universitario la Princesa, Madrid, Spain •Hospital Universitario Ramón y Cajal, Madrid, Spain •Hospital Universitario Clínico San Carlos, Madrid, Spain •Hospital Universitario 12 de Octubre, Madrid, Spain •Hospital Universitario la Paz, Madrid, Spain •and 6 more
98	A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System	Terminated	Has Results	•Neuroendocrine Tumors	•Drug: ABI-009	•Ochsner Clinic Foundation, New Orleans, Louisiana, United States
99	An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)	Completed	Has Results	•Neuroendocrine Tumors	•Drug: Everolimus (RAD001)	<ul style="list-style-type: none"> •Novartis Investigative Site, Berlin, Germany •Novartis Investigative Site, Berlin, Germany •Novartis Investigative Site, Chemnitz, Germany •Novartis Investigative Site, Erlangen, Germany •Novartis Investigative Site, Essen, Germany •Novartis Investigative Site, Homburg, Germany •Novartis Investigative Site, Kassel, Germany •Novartis Investigative Site, Mainz, Germany •Novartis Investigative Site, Muenchen, Germany •Novartis Investigative Site, Osnabrück, Germany •Novartis Investigative Site, Weiden, Germany
100	Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver	Recruiting	No Results Available	<ul style="list-style-type: none"> •Neuroendocrine Tumors •Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors 	•Drug: 177Lu-DOTATATE	•Memorial Sloan Kettering Cancer Center, New York, New York, United States

3,343 additional studies not shown